VISHNUVishnu Chemicals Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Vishnu Chemicals Limited engages in the manufacture and sale of chromium chemicals in India. The company offers chromium chemicals, such as sodium dichromate, basic chromium sulphate, chromic acid, chrome oxide green, white sodium sulphate, and potassium dichromate; and barium barium carbonate, precipitated barium sulphate, and sodium sulphide. Its products are used in pharmaceuticals, consumer goods, glass, pigments and dyes, leather, automobiles, and wood preservatives markets. The company also supplies its products to Asia, China, South East Asia, Europe, the United Kingdom, North America, South and Central America, Africa, and internationally. Vishnu Chemicals Limited was incorporated in 1989 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VISHNU — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Debt/Equity: 0.49
- • Promoter holding: 70.1%
- • RSI: 68
- • MACD: bullish
- • Price vs EMA21: above
- • 1-month return: +18.9%
Bull case
- • Debt/Equity: 0.49
- • Promoter holding: 70.1%
- • RSI: 68
- • MACD: bullish
Bear case
- • PEG ratio: 2.90
- • Dividend yield: 0.05%
- • Volume: 0.5x 20-day average
- • Beta: -0.03
Key risks
- • PEG ratio: 2.90
- • Dividend yield: 0.05%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹24.28). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.